New combo therapy shows promise in early trial for liver-metastatic colorectal cancer
NCT ID NCT02837263
First seen May 01, 2026 · Last updated Jun 14, 2026 · Updated 9 times
Summary
This early-phase study tested the safety of combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) to the liver in 15 adults with colorectal cancer that had spread only to the liver. The goal was to see if this combination could prevent the cancer from coming back within one year after all visible tumors were surgically removed. The study focused on safety and recurrence rates, not on a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.